Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor

Carlsson K S, Astermark J, Donfield S, Berntorp E

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Arthralgia /drug therapy /economics /etiology; Autoantibodies /blood; Blood Coagulation Factors /economics /therapeutic use; Child; Child, Preschool; Cost-Benefit Analysis; Cross-Over Studies; Drug Costs; Factor VIIa /economics /therapeutic use; Factor VIII /immunology; Hemarthrosis /drug therapy /economics /etiology; Hemophilia A /complications /drug therapy /economics /immunology; Hemostatics /economics /therapeutic use; Humans; Middle Aged; Pain Measurement; Patient Satisfaction; Recombinant Proteins /economics /therapeutic use; Sweden; Treatment Outcome; Turkey; United States

AccessionNumber
22008101403

Date bibliographic record published
23/12/2008